Reuters logo
BRIEF-Capricor Therapeutics provides update on ALLSTAR trial
May 12, 2017 / 10:39 AM / 6 months ago

BRIEF-Capricor Therapeutics provides update on ALLSTAR trial

May 12 (Reuters) - Capricor Therapeutics Inc:

* Capricor Therapeutics provides update on allstar trial

* Capricor Therapeutics Inc - ALLSTAR trial unlikely to achieve primary efficacy endpoint of change in infarct size in patients following heart attack

* Capricor Therapeutics- pre-specified administrative interim analysis demonstrated a low probability of achieving statistically-significant difference

* Capricor Therapeutics Inc - there were no safety signals in cap-1002 treatment cohort

* Capricor Therapeutics - plans to reduce scope of operations, including size of workforce, in order to focus financial resources primarily on DMD program

* Capricor Therapeutics-to initiate enrollment into randomized,double-blind, placebo-controlled, clinical trial of intravenous CAP-1002 in DMD in H2 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below